GlassScriptPhysician profile
Jose M Lopez
NPI 1427150846
$11,155.88
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $513 · 2021: $783 · 2022: $635 · 2023: $8,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,040 · Travel and Lodging: $848 · Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,040.00 |
| Travel and Lodging | $848.02 |
| Food and Beverage | $494.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $8,052.91 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $550.38 | 2019-2022 | |
| Lilly USA, LLC | $349.06 | 2019-2022 | |
| Pfizer INC. | $341.88 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $230.51 | 2019-2022 | |
| Novo Nordisk INC | $171.78 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $141.78 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $88.96 | 2019-2020 | |
| Amarin Pharma, INC. | $82.16 | 2021-2022 | |
| Abbvie INC. | $76.04 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.99 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $65.31 | 2019 | |
| Glaxosmithkline, LLC. | $59.32 | 2021-2022 | |
| Althera Pharmaceuticals LLC | $56.59 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $53.69 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $44.92 | 2021-2022 | |
| Amgen INC. | $44.92 | 2019-2023 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $44.46 | 2021 | |
| Horizon Therapeutics Plc | $43.96 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $42.31 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $42.29 | 2020-2023 | Farxiga |
| Allergan, INC. | $41.19 | 2019-2020 | |
| Tactile Systems Technology INC | $36.38 | 2020-2023 | Entre Plus, Flexitouch Plus |
| Astellas Pharma US INC | $36.14 | 2019-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $19.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.87 | 2023 | |
| Abbott Laboratories | $16.60 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.50 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $15.69 | 2021 | |
| Dynavax Technologies Corporation | $14.65 | 2023 | Heplisav-B |
| Seqirus USA INC | $14.12 | 2019 | |
| Sanofi Pasteur INC. | $13.06 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.